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Rationale and Objectives. Blood-based studies have demonstrated the potential of immunological assays to detect
tuberculosis. However lung fluid sampling may prove superior as it enables simultaneous microbiological detection of
mycobacteria to be performed. Until now this has only been possible using the expensive and invasive technique of broncho-
alveolar lavage. We sought to evaluate an immunoassay using non-invasive induced-sputum to diagnose active tuberculosis.
Methods and Results. Prospective cohort study of forty-two spontaneous sputum smear-negative or sputum non-producing
adults under investigation for tuberculosis. CD4 lymphocytes specific to purified-protein-derivative of Mycobacterium
tuberculosis actively synthesising interferon-gamma were measured by flow cytometry and final diagnosis compared to
immunoassay using a cut-off of 0.5%. Sixteen subjects (38%) were HIV-infected (median CD4 count [range]=332 cells/ml [103–
748]). Thirty-eight (90%) were BCG-vaccinated. In 27 subjects diagnosed with active tuberculosis, the median [range]
percentage of interferon-gamma synthetic CD4+ lymphocytes was 2.77% [0–23.93%] versus 0% [0–2.10%] in 15 negative for
active infection (p,0.0001). Sensitivity and specificity of the immunoassay versus final diagnosis of active tuberculosis were
89% (24 of 27) and 80% (12 of 15) respectively. The 3 positive assays in the latter group occurred in subjects diagnosed with
quiescent/latent tuberculosis. Assay performance was unaffected by HIV-status, BCG-vaccination or disease site. Combining
this approach with traditional microbiological methods increased the diagnostic yield to 93% (25 of 27) alongside acid-fast
bacilli smear and 96% (26 of 27) alongside tuberculosis culture. Conclusions. These data demonstrate for the first time that a
rapid immunological assay to diagnose active tuberculosis can be performed successfully in combination with microbiological
methods on a single induced-sputum sample.
Citation: Breen RAM, Hardy GAD, Perrin FMR, Lear S, Kinloch S, et al (2007) Rapid Diagnosis of Smear-Negative Tuberculosis Using Immunology and
Microbiology with Induced Sputum in HIV-Infected and Uninfected Individuals. PLoS ONE 2(12): e1335. doi:10.1371/journal.pone.0001335
INTRODUCTION
Prompt detection of tuberculosis (TB) infection is vital for TB
control [1]. The development of commercial interferon-gamma
(IFN-c) release assays (IGRA) has focussed attention on the use of
host immune reactivity as a marker of infection. Increasing data
suggest that blood-based IGRA have significant advantages when
investigating latent TB infection (LTBI) compared to the much
older immunoassay the tuberculin skin test (TST) [2,3,4,5].
However, both the TST and IGRA are much less helpful in the
diagnosis of active TB, especially when this is accompanied by
immune suppression such as HIV [6,7,8].
Distinct TB antigen-specific responses are found in the lung
[9,10]. Given that TB infection istransmitted typically byinhalation,
it is likely that these responses, which are typically of a much higher
frequency than found in blood, may be of greater importance than
the immunological findings within peripheral blood. Clinical studies
using bronchoscopy and broncho-alveolar lavage (BAL) to recover
lung cells have confirmed that the pulmonary T-lymphocyte
immune response can be used with excellent sensitivity to detect
active TB, including non-pulmonary and HIV-related forms
[11,12]. These early data have been confirmed in larger studies of
spontaneous sputum-smear negative cases. [13,14].
Not only is a lung-based approach an exciting advance in TB
immune-diagnostics; but also it allows direct smear and culture to
be performed on the same primary sample. Given persisting high
global rates of drug resistance and the emergence of XDR-TB, the
facility to run such immunology and microbiology tests on a single
sample is of great potential significance [15].
Obtaining lung fluid by bronchoscopy and BAL is both
expensive and invasive [16]. Recently a number of studies have
shown that non-invasive sputum induction (SI) using inhaled
hypertonic saline for TB diagnosis has a similar microbiological
yield to BAL-yet at a substantially reduced cost, and in a
significantly more patient-friendly manner [17,18]. However, cell
populations obtained by the two methods differ, which may limit
assessment of TB antigen-specific responses when using SI [19].
In this study we have investigated for the first time whether a single
sample obtained by simple SI methodology can be used to diagnose
TB promptly using immunological assays (flow cytometry and
ELISpot) in combination with traditional microbiological techniques.
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Subjects
The study was approved by the Royal Free Hospital Ethics
Committee (LREC 6236). Adults being investigated for TB who
were either (1) sputum acid-fast bacilli (AFB) smear-negative, or (2)
not producing sputum and had no positive AFB smears from non-
pulmonary samples, were recruited from our urban Teaching
Hospital between April 2005 and April 2006. Written informed
consent was obtained. Subjects continued to be investigated by
their physician independently of SI where appropriate. No subject
had commenced anti-tuberculosis medication at the time of study.
SI was performed in a portable, negative-pressure isolation
chamber(ElwynRoberts,Shropshire,UK)using3%saline delivered
via an ultrasonic nebuliser (Sunrise Medical, Wollaston, UK) for
20 minutes. Peak expiratory flow rate (PEFR) was measured every
5 minutes and induction terminated if PEFR declined by .15%, or
if chest discomfort were reported. Prior to induction subjects were
asked to clear their mouth and nose of any residual saliva or
secretions. After each five minute period and prior to any
expectoration of sputum this process was repeated. Sputum was
expectorated without assistance in to a sterile container.
Sample handling and laboratory investigation
Sputum was processed within 2 hours. An equivalent volume of
0.1% dithiothreitol solution (Sigma, UK) was added, the sample
rolled for 20 minutes at room temperature and an aliquot (usually
50% of the total sample) removed for microbiological investigation.
Flow cytometry
Absolute leucocyte, lymphocyte and CD4+ T-cell numbers were
determined by flow cytometry [20]. Detection of IFN-c synthesis
following 16 hour (overnight) incubation was performed as
previously described [11]. In brief, 5610
4 CD4 lymphocytes were
incubated with tissue culture medium (TCM) alone {negative
control}; TCM with PPD (Mycos Research, CO, USA) or TCM
with PHA (Sigma) {positive control}. Brefeldin A (Sigma) was
added after 2 hours. Harvested cells were fixed and permeabilised,
and stained for expression of CD3, CD4 and IFN-c. Lymphocytes,
identified by scatter, were gated according to CD3 expression to
produce a histogram of IFN-c producing CD4+ and CD4- T cells.
The IFN-c+ CD4+ lymphocyte frequency as a percentage of the
total CD4+ T-lymphocyte population (%CD4+IFN-c+) was
determined. The %CD4+IFN-c+ in the negative control was
subtracted from that in the PPD-stimulated sample to give a
percentage value of PPD-specific CD4+ IFN-c+ lymphocytes
(%PPD-specific CD4+IFN-c+). No samples were excluded due to
high negative control responses which had a median %CD4+IFN-
c+ value of 1.04%. This did not differ significantly between
subjects with and without active TB (1.04% versus 0.83%
respectively). Using data from early experiments an adequate
positive control response was taken as a CD3+ IFN-c+ response of
.10% (median [range] positive control response was 49.3%
[16.0–78.3]). All flow cytometry and evaluation of %PPD-specific
CD4+IFN-c+ responses was performed by RAMB.
ELISpot
ELISpot assays were also performed on induced sputum samples
as described previously [21]. Briefly 1610
5 leukocytes per well
were cultured overnight with duplicates of TCM alone [negative
control], PPD or PHA [positive control] in 96 well anti-IFN-c
(Mabtech, Stockholm, Sweden) coated PVDF-backed plates
(Millipore, Watford, UK). After overnight incubation IFN-c
spot-forming cells (SFC) were detected according to the manufac-
turer’s instructions (Mabtech). The mean of duplicate conditions
was calculated. Results are presented as background subtracted
(delta) spot-forming units (DSFU) per/10
6 cells. A negative
response to the positive control, PHA, was used to determine
assay failure, in which case the result was discounted from the data
set. Since none of the PHA treated cells produced a negative
result, no assays were excluded. All ELISpot assays and
determination of these results were performed by GADH.
Microbiology
Microscopy acid-fast bacilli (AFB) smears were prepared and
stained with auramine-O; and positive smears were confirmed
using a Ziehl-Neelsen stain. All positive cultures for Mycobacterium
tuberculosis (M.tb) were confirmed by the Mycobacterial Reference
Laboratory, London, UK.
Diagnostic definition
Clinical diagnostic decisions were made without reference to
immunological data. A final diagnosis of ‘‘active TB’’ was accepted
when (1) M.tb was cultured or (2) there was clear evidence for a
clinical diagnosis based on radiology or histology with an
appropriate response to treatment. A final diagnosis of ‘‘quiescent
or latent TB’’ was accepted if there were a clearly recorded history
of exposure to a smear positive index case with supporting
tuberculin skin test (TST) or radiological results but the clinical
decision had been made not to commence full anti-tuberculosis
therapy. A final diagnosis of ‘‘not TB’’ was accepted if an
alternative diagnosis were reached, symptoms resolved rapidly and
anti-tuberculosis therapy was not commenced. All subjects without
culture-confirmed TB have been followed up for at least
12 months for changes in their diagnostic categorisation.
Statistical assessment
Comparisons between groups were made using the Wilcoxon test.
The data were analysed using SAS version 8.2 (SAS Institute Inc,
Cary, NC).
RESULTS
Patient information
Forty-two individuals underwent sputum induction. Median age
[range] was 32 years [21–63]. Ethnic background was Black 36%
(15 of 42), Asian 33% (14 of 42), Caucasian 31% (13 of 42). 90%
(38) had received Bacille-Calmette-Guerin (BCG) vaccination.
38% (16 of 42) were HIV-infected with a median [range] blood
CD4 count of 332 cells/ml [103–748]. The subjects are described
individually in Table 1.
Active TB was diagnosed in 27 subjects of whom 26% (7 of 27)
were HIV-infected. 74% (20 of 27) were M.tb culture-positive.
56% (15 of 27) had pulmonary and 44% (12 of 27) had active TB
diagnosed at a non-pulmonary site.
Three of 42 subjects received a final diagnosis of quiescent or
latent TB. A final diagnosis of ‘‘not TB’’ was made in 12 subjects,
all of whom had been previously BCG-vaccinated and 7 of 12
(58%) were HIV-infected. These data are shown in Table 2.
Induced-sputum cell yields and phenotypes
No induction had to be terminated prematurely and no significant
symptoms or reduction in PEFR were noted. The median time
after starting induction at which sputum expectoration com-
menced was 10 minutes [2–20] and the median volume
expectorated was 5 mls [1–20]. The median absolute yield of
TB Immuno-Diagnosis
PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1335Table 1. Description of 42 sputum smear-negative or sputum non-producing subjects undergoing sputum induction for the
investigation of possible tuberculosis (subjects are categorised by final diagnoses of active TB; quiescent or latent TB; and not TB,
and percentage value of PPD-specific CD4+ IFN-c+ lymphocytes [%PPD-specific CD4+IFN-c+])
..................................................................................................................................................
Country of
origin Age BCG+ HIV+
Blood CD4
count (cells/ul) Final diagnosis
AFB smear
of IS
IS culture
for Mtb
%PPD-specific
CD4+ IFN-c+
Angola 34 Yes Yes 350 Culture-confirmed Pulmonary TB Negative Positive 0%
Egypt 29 Yes No na Culture-confirmed Cervical LN TB Negative Negative 0%
Pakistan 25 Yes No na Culture-confirmed Testicular and pulmonary TB (no
respiratory symptoms)
Positive Positive 0.13%
Ghana 32 Yes Yes 350 Culture-confirmed Pulmonary TB Negative Positive 0.67%
Bangladesh 25 Yes No na Culture-confirmed Cervical and pulmonary TB (normal CXR) Negative Positive 0.67%
Vietnam 32 No No na Culture-confirmed Cervical LN TB Negative Negative 0.92%
India 21 Yes No na Culture-confirmed Cervical LN TB Negative Negative 1.09%
India 29 Yes No na Presumptive Pulmonary TB Negative Negative 1.14%
Somalia 21 Yes No na Culture-confirmed Pulmonary TB Negative Positive 1.33%
Somalia 32 Yes No na Presumptive Abdominal TB Negative Negative 1.44%
Iran 34 Yes No na Culture-confirmed Pulmonary TB Negative Positive 1.81%
Somalia 21 No No na Culture-confirmed Cervical and pulmonary TB (normal CXR) Negative Positive 2.09%
Brazil 31 Yes Yes 748 Culture-confirmed Mediastinal LN TB Negative Negative 2.29%
England 29 Yes No na Culture-confirmed Pulmonary TB Negative Positive 2.77%
South Africa 32 Yes Yes 219 Presumptive Pulmonary TB Negative Negative 2.96%
Pakistan 24 Yes No na Culture-confirmed Pulmonary TB Negative Negative 3.62%
Zimbabwe 54 Yes No na Presumptive Pericardial TB Negative Negative 3.75%
Pakistan 31 Yes No na Presumptive Cervical LN TB + erythema nodosum Negative Negative 4.17%
Zimbabwe 53 No Yes 612 Presumptive Mediastinal and abdominal LN TB Negative Negative 4.49%
Ireland 36 Yes Yes 493 Culture-confirmed Pleural TB Negative Negative 4.72%
Nepal 27 Yes No na Presumptive Mediastinal LN TB Negative Negative 6.98%
Wales 63 Yes Yes 408 Culture-confirmed Pulmonary TB Positive Positive 7.76%
England 55 Yes No na Culture-confirmed Pulmonary TB Negative Positive 8.85%
England (Indian descent) 21 Yes No na Culture-confirmed Mediastinal LN TB Negative Negative 9.94%
Gambia 23 No No na Culture-confirmed Pulmonary TB Positive Positive 15.93%
Bulgaria 33 Yes No na Culture-confirmed Pulmonary TB Positive Positive 16.27%
India 28 Yes No na Culture-confirmed Cervical LN TB Negative Negative 23.93%
England 61 Yes No na Quiescent/latent TB (TST +. Previous contact of smear+ TB.
Concurrent brain tumour)
Negative Negative 0.72%
Ireland 31 Yes Yes 459 Quiescent/latent TB (Recent contact of smear+ TB. IDU.
Scar on CXR)
Negative Negative 1.94%
Nigeria 30 Yes Yes 205 Quiescent/latent TB (Recent contact of smear+ TB) Negative Negative 2.10%
DRC 29 Yes Yes 103 Cough of uncertain cause Negative Negative 0%
England (African descent) 30 Yes No na Sarcoidosis Negative Negative 0%
India 46 Yes No na LRTI Negative Negative 0%
South Africa 27 Yes No na LRTI Negative Negative 0.06%
Pakistan 32 Yes No na LRTI Negative Negative 0%
Spain 34 Yes Yes 332 Fever of uncertain cause. Resolved with anti-HIV treatment Negative Negative 0.12%
Zimbabwe 36 Yes Yes 230 Previous MAI Negative Negative 0%
England 34 Yes Yes 303 LRTI Negative Negative 0%
China 35 Yes Yes 313 LRTI Negative Negative 0%
Nigeria 53 Yes Yes 102 Multiple Enlarged LNs. Resolved with anti-HIV therapy Negative Negative 0%
Zimbabwe 39 Yes Yes 150 SLE with cough and fever. Resolved with immunosuppression Negative Negative 0.11%
India 31 Yes No na LRTI Negative Negative 0%
Abbreviations: AFB=acid-fast bacilli; BCG+=Bacille-Calmette-Guerin vaccinated; CXR=chest radiograph; DRC=Democratic Republic of Congo; HIV+=Human
immunodeficiency virus positive; IDU=injecting drug user; IS=induced-sputum; LN=lymph node; LRTI=lower respiratory tract infection; Mtb=Mycobacterium
tuberculosis; na=not applicable; ND=not done; SLE=systemic lupus erythematosis; TST=tuberculin skin test; TB=tuberculosis
doi:10.1371/journal.pone.0001335.t001
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PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1335CD45+ leucocytes was 6.6610
6 [1.0–22.5], the percentage of
CD45+ leucocytes that were lymphocytes was 4.90% [0.60–
41.10%] and the ratio of CD4+ to CD8+ lymphocytes was 1.88
[0.15–29.99].
PPD-specific IFN-c response versus final diagnosis
In those for whom the final diagnosis was active TB the median
[range] %PPD-specific CD4+IFN-c+ was 2.77% [0–23.93%].
This was unaffected by HIV co-infection: 2.96% [0–7.76%] for
HIV/TB versus 2.43% [0–23.93%] for TB alone (p=0.87)
(Figure 1). In subjects whose final diagnosis was not active TB,
the median [range] %PPD-specific CD4+IFN-c+ was 0% [0–
2.10%] (p,0.0001 versus active TB). Delineation of the non-
active TB group on the basis of whether the final clinical diagnosis
was quiescent/latent TB or not TB revealed %PPD-specific
CD4+IFN-c+ values of 1.94% [0.72%–2.10%] versus 0% [0–
0.12%] respectively (Figure 1).
Induced-sputum as a diagnostic tool–Immunoassay
alone and in combination with AFB smear or TB
culture
From ROC curve analysis (data not shown), a post-hoc %PPD-
specific CD4+IFN-c+ value of $0.5% was selected to define a
positive assay. Using this, the assay had a sensitivity of 89%
(positive in 24 of 27 of subjects diagnosed with active TB [17 of 20
(85%) with culture-confirmed M.tb and 7 of 7 (100%) who
received a presumptive diagnosis]); and a specificity of 80%
(negative result in 12 of 15 of subjects where active TB was
discounted). All 12 subjects with a final diagnosis of ‘‘not TB’’ had
a negative assay.
Amongst those subjects with a final diagnosis of active TB the
same induced-sputum sample used for the immunoassay was AFB
smear-positive in 15% (4 of 27) of cases; and M.tb culture-positive
in 48% (13 of 27). It should be noted that culture-confirmation of
M.tb was obtained in 87% (13 of 15) of pulmonary cases using a
single induced-sputum, but only 13% (2 of 15) with spontaneously
expectorated sputum in the same subjects. When results were
combined using a strategy for prompt diagnosis of AFB smear
followed, if negative, by the immunoassay, 93% (25 of 27) had a
positive result (4 of 27 [15%] smear-positive and 21 of the
remaining 23 [91%] immunoassay-positive). With a strategy of
immunoassay and culture, 96% of subjects (26 of 27) were positive
(13 [48%] culture-positive, 24 [89%] immunoassay positive and 13
[48%] positive by immunoassay alone). The results according to
final clinical diagnosis and site of active TB are displayed in
Table 2.
Induced sputum flow cytometry versus ELISpot
In 9 subjects the IFN-c response to PPD was measured on the
same sample using flow cytometry and ELISpot. In 6 of these the
final diagnosis was active TB (3 with pulmonary disease).
Equivalent results with both methods were found in all 9 subjects
(Table 3; Figure 2).
Table 2. Immunoassay and microbiology results alone and in combination compared to final diagnosis.
..................................................................................................................................................
Active TB n=27 Latent/quiescent TB n=3 Not TB n=12
Active pulmonary TB
n=15
Active non-pulmonary TB
n=12
HIV+ 7 (26%) 2 (67%) 7 (58%) 4 (27%) 3 (25%)
BCG+ 23 (85%) 3 (100%) 12 (100%) 13 (87%) 10 (83%)
Mtb culture+ from any site 20 (74%) 0 (0%) 0 (0%) 13 (87%) 7 (58%)
Mtb culture+ from IS 13 (48%) 0 (0%) 0 (0%) 13 (87%) 0 (0%)
AFB smear+ from IS 4 (15%) 0 (0%) 0 (0%) 4 (27%) 0 (0%)
Immunoassay+ 24 (89%) 3 (100%) 0 (0%) 13 (87%) 11 (92%)
AFB smear or immunoassay+ 25 (93%) 3 (100%) 0 (0%) 14 (93%) 11 (92%)
IS Mtb culture+ or
immunoassay+
26 (96%) 3 (100%) 0 (0%) 15 (100%) 11 (92%)
Subjects diagnosed with active TB are further divided according to whether this was pulmonary or non-pulmonary (italics)
Abbreviations: AFB=acid-fast bacilli; BCG+=Bacille-Calmette-Guerin vaccinated; HIV+=HIV-infected; IS=induced-sputum; Mtb=Mycobacterium tuberculosis;
TB=tuberculosis
doi:10.1371/journal.pone.0001335.t002
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Figure 1. A comparison of final diagnosis against %PPD-specific
CD4+IFN-c+ responses following overnight stimulation of induced-
sputum in 42 spontaneous sputum smear negative subjects with
possible tuberculosis (medians shown as horizontal bars). The
suggested diagnostic cut-off of 0.5% is indicated by the hatched line.
doi:10.1371/journal.pone.0001335.g001
TB Immuno-Diagnosis
PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1335DISCUSSION
This is the first study to demonstrate that a single induced-sputum
sample can be used for combined immunological and microbio-
logical TB diagnosis. In 42 individuals (38% of whom were HIV-
infected) who were either not spontaneously producing sputum or
in whom this was AFB smear-negative, our immunoassay had a
sensitivity of 89% (24 of 27 positive) and specificity of 80%
compared to a final clinical diagnosis of active TB. Although
somewhat smaller numbers, these results compare very well with
those achieved in blood in HIV-uninfected subjects [7], and ours
reported previously using BAL in a similar population [14].
Combining our lung-orientated immunological approach with
traditional microbiology produced prompt identification (induced-
sputum AFB smear or immunoassay-positive) in 93% of cases; and
overall identification (induced-sputum TB culture or immunoassay
positive) in 96% of those with active TB at any body site. It should
be noted that of the 15 subjects with active pulmonary TB, 4 were
AFB smear-positive and 13 were immunoassay-positive on a single
induced sputum sample. Thus the latter greatly increased the
chance of prompt diagnosis of active, infectious pulmonary TB.
The induced sputum immunoassay was also unaffected by HIV
status, TB disease site, and BCG vaccination. The similar results
obtained using the different methodologies of flow cytometry and
ELISpot also demonstrate that the potential of this sputum-based
method is not limited to one technique.
Confounding positive responses from BCG-vaccinated individ-
uals without TB have been observed using both the tuberculin skin
test (TST) and PPD-based blood assays [22]. This has led to the
use of smaller antigens encoded in the region of difference 1 (RD1)
portion of the genome of M.tb, which is absent in BCG-strains
[23]. However, in our lung-based assay, despite all 12 subjects with
a clinical diagnosis of ‘‘not TB’’ having received BCG, none had
evidence of a detectable pulmonary PPD response. We believe this
striking finding reflects the organ-specific pathway taken by
vaccination-generated BCG-specific memory lymphocytes ie.
trafficking through blood and homing to the skin whilst avoiding
the lung [24,25]. Apart from the insight this offers for future TB
vaccination strategies, we feel that these data support the use of
PPD, which as a rich antigen mixture, generates higher frequency
responses than RD-1 encoded antigens and therefore is likely to be
beneficial in the investigation of a condition associated with
immune suppression and CD4 lymphopenia in HIV-infected and
HIV-uninfected individuals [26,27,14].
The sub-optimal specificity observed represents positive assays
occurring in 3 subjects with a final diagnosis of quiescent or latent
TB. Interestingly these individuals had co-existent conditions
which traditionally make TB diagnosis difficult (2 HIV-infection,
and 1 terminal malignancy) and reduce the sensitivity of the TST.
Given this, it could be argued that a positive result is not such a
bad thing as it alerts the clinician not to discount TB. That positive
results are found in subjects with both quiescent or latent TB and
those with active TB confounds all current immune-based assays
using interferon-c expression as the primary readout [28,29].
However we have previously observed that some of the individuals
with these apparent ‘‘false-positive’’ results may develop clearly
active TB during follow up [14].
When seeking to delineate between different stages of TB we
believe that flow-cytometry adds more value than other immune-
based tests, as it can define not only the numbers of cells producing
a given cytokine but also the cell phenotype responsible in various
states of TB infection. Early studies assessing the expression of
both interferon-c and surface markers of differentiation and
memory status such as CD27 have hinted at the promise of such a
multi-parameter flow-cytometry based approach [30].
The focus of this study has been the assessment of our induced-
sputum assay in diagnosing active TB. The methodology is
applicable also to studies of TB pathogenesis. To date, lung-based
immunological studies have relied upon bronchoscopy. Although
this usefully obtains cell-rich samples, its invasive nature makes it
an unpleasant test. Sputum induction offers the possibility of
longitudinal assessment of the pulmonary immune response during
treatment with good subject acceptability and at greatly reduced
cost. We believe that this approach opens up an important area of
research which might yield markers of treatment response and
even TB cure (31).
Figure 2. Cytometric dot plots and ELISpot wells from a subject with
active tuberculosis, demonstrating interferon (IFN)-c synthesis in
response to overnight incubation of induced-sputum with purified-
protein derivative of Mycobacterium tuberculosis (PPD). Panel A:
Proportion of CD4+ lymphocytes producing IFN-c after incubation with
no antigen (Ag) added. Panel B: Proportion of CD4+ lymphocytes
producing IFN-c after incubation with PPD. Panel C: ELISpot wells
showing the IFN-c T-cell response after incubation with no antigen
added. Panel D: ELISpot wells showing the IFN-c T-cell response after
incubation with PPD.
doi:10.1371/journal.pone.0001335.g002
Table 3. Comparison of flow cytometry and ELISpot
techniques in assessing PPD-specific interferon-gamma
responses
......................................................................
Final diagnosis
Flow cytometry-%PPD-
specific CD4+IFN-c+
ELISpot-IFN-c
SFU/10
6 cells
Mediastinal and abdominal lymph
node TB
4.49% 725
Mediastinal lymph node TB 6.98% 1020
Pulmonary TB 8.85% 725
Pulmonary TB 15.93% 535
Pulmonary TB 16.27% 3405
Cervical lymph node TB 23.93% 4120
Not TB 0% 5
Not TB 0.06% 10
Not TB 0.12% 0
Abbreviations: SFU=spot forming units; TB=tuberculosis;
doi:10.1371/journal.pone.0001335.t003
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PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1335These data reveal for the first time how a lung-orientated
approach combining a novel immunoassay with traditional
microbiology can rapidly diagnose active TB in individuals with
smear-negative disease using a single induced-sputum sample.
Although a relatively small study performed in a research setting,
we believe that our data warrant further work assessing the
usefulness of induced-sputum as an alternative to both blood and
BAL samples when investigating possible TB.
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